Business and partner highlights from the first quarter of 2026 and recent weeks included the following: (Businesswire) - May 8, 2026 - "The potentially registrational trial with IMVT-1402 in difficult-to-treat rheumatoid arthritis is fully enrolled, with topline data expected in the second half of this year. Topline data from the proof-of-concept trial with IMVT-1402 in cutaneous lupus erythematosus is also expected in the second half of this year; Potentially registrational studies with IMVT-1402 in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease remain on track with topline data in GD and MG expected in 2027."
P2 data • P3 data • Trial status • Cutaneous Lupus Erythematosus • Grave's Disease • Myasthenia Gravis • Rheumatoid Arthritis • Sjogren's Syndrome
|